Loading...
•
Dec 31, 2021
Cardiff Oncology Q4 2021 Earnings Report
Cardiff Oncology reported results for Q4 2021, highlighted by clinical progress in its KRAS-mutated mCRC program, a $15 million equity investment from Pfizer, and strengthened leadership with key appointments.
Key Takeaways
Cardiff Oncology reported fourth-quarter and full-year 2021 results, highlighting continued progress in its lead KRAS-mutated metastatic colorectal cancer program, a $15 million equity investment from Pfizer, and strategic leadership appointments. The company's cash, cash equivalents, and short-term investments totaled approximately $141 million as of December 31, 2021.
Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those seen in historical control trials.
Received $15 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.
Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer to join Cardiff Oncology Scientific Advisory Board.
Strengthened leadership team with appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, R.Ph., as senior vice president (SVP), regulatory affairs.
Forward Guidance
Cardiff Oncology is focused on advancing its mCRC clinical program, exploring synergistic combinations with onvansertib in other cancer indications, and leveraging onvansertib in other cancer indications.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...